Linagliptin: Phase III data

A meta-analysis of 8 double-blind Phase III trials in patients with Type II diabetes showed that once-daily linagliptin (n=3,319) led to a significantly lower incidence of cardiovascular death, non-fatal stroke, non-fatal MI and hospitalization for unstable angina pectoris, the composite primary endpoint, vs. the comparators placebo, glimepiride or voglibose (n=1,920; 5.3 vs. 16.8 events per 1,000 patient-years, p<0.05). Data were presented at the American Diabetes Association meeting in San Diego. ...